Efficacy of Agomelatine in Depressive Disorders with Anxiety
- 55 Downloads
An open six-week study of the efficacy of agomelatine was performed in 35 patients with single depressive episodes or recurrent depression (ICD-10 diagnoses) and clinically severe anxiety. Agomelatine was found to be highly effective and safe in the treatment of mild and moderate depression combined with anxiety disorders. Decreases in the severity of the symptoms of depression and sleep disorders were seen from treatment week 1, with reductions in anxiety from treatment week 2. By the end of the study, therapeutic effects were seen in 71.9% of patients and the remission criteria were achieved in 68.8% of patients.
Keywordsdepression anxiety agomelatine sleep disorders
Unable to display preview. Download preview PDF.
- 1.O. P. Vertogradova, “Possible approaches to the typology of depression,” in: Depression (psychopathology, pathogenesis), Moscow (1980), pp. 9–15.Google Scholar
- 2.V. N. Krasnov, Affective Spectrum Disorders, Moscow (2011), pp. 146–156.Google Scholar
- 3.S. N. Mosolov, E. G. Kostyukova, A. V. Gorodinchev, et al., “Efficacy and tolerance of agomelatine in depressive states,” 15, 15–24 (2011).Google Scholar
- 4.A. A. Pribytkov, “Comparative analysis of the antidepressant activity and effects on sleep disorders of agomelatine (Valdoxan) and fluvoxamine (Fevarin),” Obozr. Psikhiatr. Med. Psikhol. im. Bekhtereva, No. 4, 38–40 (2010).Google Scholar
- 7.B. Bandelow, J. Zohar, E. Hollander, et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision,” World J. Biol. Psychiatry, 9, No. 4, 248–312 (2008).CrossRefPubMedGoogle Scholar
- 11.D. R. Dolnak, “Treating patients for comorbid depression, anxiety disorders, and somatic illnesses,” J. Am. Osteopath. Assoc., No. 2, 1–8 (2006).Google Scholar
- 13.P. S. Foroushani, J. Schneider, and N. Assareh, “Meta-review of the effectiveness of computerized CBT in treating depression,” BMC Psychiatry , No. 11, 131 (2011).Google Scholar
- 18.S. Kasper, G. Hajak, K. Wulff, et al., “Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline,” J. Clin. Psychiatry, 71, No. 2, 109–120 (2010).CrossRefPubMedGoogle Scholar
- 21.R. J. Kuzel, “Treating comorbid depression and anxiety,” J. Fam. Pract., 43, 45–53 (1996).Google Scholar
- 24.H. Lôo, A. Hale, and H. D’haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, No. 5, 239–247 (2002).CrossRefPubMedGoogle Scholar
- 26.A. McIntyre, A. Gendron, and A. McIntyre, “Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study,” Depress. Anxiety, 24, No. 7, 487–494 (2007).CrossRefPubMedGoogle Scholar